RxDoctor Payments Data

Sarah Adams, MD

Family Medicine · Ponte Vedra, FLNPI 1154959815

Payments from drug & device makers

$1,920in general payments, 2019–2025

Across 69 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$398
  • Novo Nordisk$310
  • AbbVie$218
  • Lilly USA, LLC$216
  • Merck$143
  • GSK$111
  • plus $524 from 14 others

What the payments were for

  • Food & beverage$1,920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,920 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$101,882
Medicare patients
202
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$54,198
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,046
SynthroidLevothyroxine Sodium27$1,951
Atorvastatin Calcium133$1,495
Candesartan Cilexetil11$1,257
Rosuvastatin Calcium117$1,229
Levothyroxine Sodium97$1,095
Duloxetine Hcl24$1,068
Metoprolol Succinate43$810
Lisinopril89$748
Estradiol16$688
Wixela InhubFluticasone Propion/Salmeterol12$663
Albuterol Sulfate HfaAlbuterol Sulfate26$644
Losartan Potassium68$581
Oxybutynin Chloride ErOxybutynin Chloride12$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$216$54,19836 claims
AbbVieSynthroid$218$1,95127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ponte Vedra

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →